These results, along with earlier studies on MCC950, indicate that both OLT1177 and MCC950 may serve as promising therapeutic options for mitigating post-stroke neuroinflammation by inhibiting NLRP3 inflammasome activation. Here, NLRP3 is linked to stroke disorder.